Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up – Still a Buy?

Summit Therapeutics PLC (NASDAQ:SMMT)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $12.73, but opened at $13.27. Summit Therapeutics shares last traded at $13.2520, with a volume of 727,251 shares.

Key Stories Impacting Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Partner Akeso reported positive topline results from the Phase 3 HARMONi-GI1 trial in advanced biliary tract cancer. Ivonescimab plus chemotherapy delivered a statistically significant overall-survival benefit versus durvalumab plus chemotherapy, potentially strengthening the drug’s commercial opportunity beyond non-small-cell lung cancer. HARMONi-GI1 biliary tract cancer results
• Positive Sentiment: The HARMONi-GI1 findings were described as outperforming AstraZeneca’s Imfinzi, raising expectations for ivonescimab’s competitive positioning in gastrointestinal cancers. Ivonescimab outperforms Imfinzi
• Positive Sentiment: Results from the global Phase 3 HARMONi trial, published in The Lancet Oncology, showed a statistically significant and clinically meaningful progression-free-survival improvement for ivonescimab plus chemotherapy in EGFR-mutated non-small-cell lung cancer. This adds peer-reviewed support for Summit’s lead program while investors await pivotal global data and potential FDA decisions. Global HARMONi trial publication
• Positive Sentiment: Seeking Alpha upgraded Summit to Buy, citing improving sentiment and approaching clinical and regulatory catalysts. The upgrade may be contributing to greater buying interest despite the stock’s high volatility. Summit Therapeutics rating upgrade
• Neutral Sentiment: HC Wainwright reaffirmed a Neutral rating, indicating that some analysts remain cautious while awaiting additional efficacy, regulatory, and commercial evidence.
• Negative Sentiment: Summit’s cash may cover only four to five quarters, while aggressive pipeline expansion and elevated operating expenses increase cash-burn and going-concern risks. The company also recently reported a quarterly loss slightly wider than analysts expected.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on SMMT shares. Piper Sandler dropped their price target on shares of Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, May 1st. Guggenheim reiterated a “buy” rating on shares of Summit Therapeutics in a research note on Wednesday. Wall Street Zen cut Summit Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Friday, July 17th. Finally, Jefferies Financial Group set a $15.00 price objective on Summit Therapeutics in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $24.07.

Summit Therapeutics Stock Performance

The firm has a market cap of $11.35 billion, a P/E ratio of -12.71 and a beta of -1.23. The company’s 50 day moving average is $14.11 and its 200 day moving average is $16.18.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings data on Thursday, July 23rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, equities research analysts anticipate that Summit Therapeutics PLC will post -1.2 EPS for the current year.

Insider Activity at Summit Therapeutics

In related news, CEO Mahkam Zanganeh purchased 3,810,000 shares of the business’s stock in a transaction on Friday, June 12th. The stock was acquired at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the purchase, the chief executive officer owned 573,883,879 shares of the company’s stock, valued at approximately $7,529,356,492.48. This trade represents a 0.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert W. Duggan bought 3,810,000 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the purchase, the chief executive officer directly owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. The trade was a 0.67% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 7,870,000 shares of company stock valued at $103,616,900. 83.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Summit Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its holdings in shares of Summit Therapeutics by 334.8% during the 2nd quarter. California State Teachers Retirement System now owns 27,785 shares of the company’s stock valued at $405,000 after buying an additional 21,394 shares in the last quarter. AXQ Capital LP boosted its stake in Summit Therapeutics by 98.1% in the second quarter. AXQ Capital LP now owns 93,624 shares of the company’s stock worth $1,364,000 after buying an additional 46,356 shares in the last quarter. Nykredit A S purchased a new stake in Summit Therapeutics in the second quarter worth approximately $111,000. Two Sigma Securities LLC bought a new position in Summit Therapeutics during the second quarter valued at approximately $182,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Summit Therapeutics by 13.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 90,338 shares of the company’s stock valued at $1,316,000 after acquiring an additional 10,642 shares during the last quarter. 4.61% of the stock is currently owned by institutional investors.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.